SEATTLE, WASHINGTON--(Marketwire - Sept. 4, 2012) - VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) is pleased to announce the final results of the pilot study undertaken at the University of Chicago, using its VMS™ diagnostic tool, in Pulmonary Arterial Hypertension (PAH). The results show a non-statistical average difference between VMS™ and Cardiac Magnetic Resonance Imaging (CMR) of 0.65% for volumes from 75ml (normal hearts) to 425 ml (dilated hearts) with 95% confidence limits of +/- 3%. There was an excellent agreement between the two techniques over the entire volume range with correlation coefficients of r2=0.97 for both when the heart was filled with blood (end-diastolic volume) and when it was finished ejecting blood (end-systolic volume).
To view the tables associated with this release, please see the following link: http://media3.marketwire.com/docs/904vpt_tables.pdf
"We would like to thank the team at the University of Chicago for the excellent performance of the study. The Company is currently in a multi-centre pivotal clinical trial, for submission to the FDA, using the PAH application and is enrolling patients at major cardiac centres," said Dr. George Adams, CEO of VentriPoint. "The excellent 95% Confidence Limits of 3% is very encouraging as the target for the pivotal trial is 10% or less."
The paper entitled "Three-Dimensional Reconstruction of the Right Ventricle from Two-Dimensional Echocardiographic Images: Validation of Volume Measurements Against MRI" was authored by Nicole Bhave, Benjamin H. Freed, Amit R. Patel, Megan Yamat, Lynn Weinert, James Bodtke, Roberto M. Lang, and Mardi Gomberg-Maitland and was presented on Monday September 3rd at the European Respiratory Society Annual Congress in Vienna.
About the European Respiratory Society
The European Respiratory Society was founded in London in 1990 from the merger of the Societas Europaea Physiologiae Clinicae Respoiratoriae (SEPCR, founded 1966) with the European Society of Pneumology (SEP, founded 1981), it is unique in bringing together basic science with clinical practice within a single entity. The Annual Congress, which is the largest respiratory meeting in the world, brings together the membership now standing at some 10,000 to further the awareness of lung health and improving prevention, management and treatment of lung disease.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool for pulmonary arterial hypertension and the congenital heart disease, TOF, and is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release